RAPGEF3 and prostate carcinoma: What’s more, EPAC1 can either promote or attenuate cancer progression in breast cancer [67,68,69], leukaemia [70,71], neuroendocrine cancer [72], ovarian cancer [73,74,75,76] and prostate cancer [77,78,79,80].